Table 1.
Epidemiological and clinical characteristics of episodes of P. aeruginosa bloodstream infection in patients with and without septic shock.
| Characteristics | Overall n = 1213 |
No Septic Shock n = 802 (%) |
Septic Shock n = 411 (%) |
p-Value |
|---|---|---|---|---|
| Age (years, median, range) | 60 (IQR 20) | 60 (IQR 21) | 60 (IQR 19) | 0.423 |
| Male sex | 749 | 475 (59.2) | 274 (66.7) | 0.012 |
| Co-morbidities | ||||
| Chronic heart disease | 150 | 94 (11.7) | 56 (13.6) | 0.340 |
| Chronic obstructive pulmonary disease | 118 | 71 (8.9) | 47 (11.4) | 0.151 |
| Diabetes mellitus | 137 | 99 (12.3) | 38 (9.2) | 0.107 |
| Chronic liver disease | 85 | 54 (6.7) | 31 (7.5) | 0.601 |
| Other comorbidities a | 146 | 102 (13.3) | 44 (11.4) | 0.372 |
| Solid tumors | 299 | 162(20.2) | 137 (33.3) | <0.001 |
| Lung cancer | 88 | 50 (30.9) | 38 (27.7) | |
| Gastrointestinal cancer | 52 | 25(15.4) | 27 (19.7) | |
| Breast cancer | 28 | 18 (11.1) | 10 (7.3) | |
| Genitourinary cancer | 29 | 11 (6.8) | 18 (13.1) | |
| Other solid tumors | 102 | 58 (35.8) | 44 (32.1) | |
| Hematologic malignancies | 914 | 640 (79.8) | 274 (66.7) | <0.001 |
| Acute myeloid leukemia | 310 | 233 (36.4) | 77 (28.1) | |
| Non-Hodgkin lymphoma | 271 | 179 (28) | 92 (33.6) | |
| Acute lymphoblastic leukemia | 97 | 58 (9.1) | 39 (14.2) | |
| Other hematologic malignancies | 236 | 170 (26.6) | 66 (24.1) | |
| Hematopoietic stem cell transplant | 289 | 199 (24.8) | 90 (21.9) | 0.259 |
| High-risk MASCC index score b | 762 | 422 (57.4) | 340 (92.6) | <0.001 |
| Profound neutropenia (0.1 × 109/L) | 725 | 464 (59.6) | 261(65.1) | 0.069 |
| Severe mucositis (grade III–IV) | 169 | 109 (13.7) | 60 (14.9) | 0.574 |
| Corticosteroid therapy (1 month) | 630 | 402 (51.2) | 228 (56.6) | 0.079 |
| Previous antibiotic therapy (1 month) | 663 | 446 (56.7) | 217 (53.3) | 0.259 |
| Prior quinolone prophylaxis | 195 | 134 (16.9) | 61 (14.9) | 0.377 |
| Prior chemotherapy (1 month) | 1033 | 678 (84.9) | 355 (86.6) | 0.439 |
| Urinary catheter | 205 | 99 (12.8) | 106 (26) | <0.001 |
| Nosocomial acquisition | 691 | 475 (59.2) | 216 (52.6) | 0.026 |
| Source of bloodstream infection | ||||
| Endogenous source | 452 | 329 (41) | 123 (29.9) | <0.001 |
| Pneumonia | 310 | 154 (19.2) | 156 (38) | <0.001 |
| Catheter-related infection | 112 | 78 (9.7) | 34 (8.3) | 0.408 |
| Neutropenic enterocolitis | 71 | 52 (6.5) | 19 (4.6) | 0.191 |
| Skin and soft tissue infection | 70 | 49 (6.1) | 21 (5.1) | 0.480 |
| Urinary tract | 51 | 33 (4.1) | 18 (4.4) | 0.828 |
| Other abdominal sources c | 45 | 25 (3.1) | 20 (4.9) | 0.127 |
| Perineal infection | 34 | 29 (3.6) | 5 (1.2) | 0.017 |
| Mucositis | 24 | 20 (2.5) | 4 (1) | 0.083 |
| Unknown origin | 15 | 11 (1.4) | 4 (1) | 0.785 |
| Gangrenous ecthyma | 51 | 32 (4) | 19 (4.7) | 0.597 |
| MDRPA d | 308 | 169 (21.1) | 139 (33.8) | <0.001 |
| XDRPA e | 234 | 122 (15.3) | 112 (27.5) | <0.001 |
a other comorbidities included chronic renal disease and cerebrovascular disease; b MASCC: Multinational Association for Supportive Care in Cancer; c other abdominal sources included cholangitis, peritonitis, and intra-abdominal abscesses; d MDRPA: multidrug-resistant Pseudomonas aeruginosa; e XDRPA: extensively drug-resistant Pseudomonas aeruginosa.